Standard Biotools Price To Sales vs. Current Valuation

Based on Standard Biotools' profitability indicators, Standard Biotools may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess Standard Biotools' ability to earn profits and add value for shareholders.Year-over-year analysis suggests Price To Sales Ratio is positioned to edge lower. A year ago, Standard Biotools reported Price To Sales Ratio at 5.72. Recent filings indicate that Gross Profit continues increasing. It was pegged at 42.54 Million in the prior reporting cycle. As of now, The current year's Gross Profit Margin is projected to rise to 0.62, while Pretax Profit Margin is moving lower toward -1.19 .

Standard Biotools Price To Sales Ratio

4.42

Recent disclosures position Days Sales Outstanding within a decreasing cycle. A year ago, Standard Biotools reported Days Sales Outstanding at 57.45. As of now, The current year's Days Of Sales Outstanding is projected to rise to 81.99, while Price To Sales Ratio is moving lower toward 4.42. Recent disclosures position Interest Income within an increasing cycle. A year ago, Standard Biotools reported Interest Income at 9.18 Million. As of now, The current year's Net Interest Income is projected to rise to approximately 9.6 M, while Accumulated Other Comprehensive Income is projected to grow to about -1.4 M. Recent filings indicate that Gross Profit continues increasing. It was pegged at 42.54 Million in the prior reporting cycle. As of now, The current year's Gross Profit Margin is projected to rise to 0.62, while Pretax Profit Margin is moving lower toward -1.19 .

	Current Value	Last Year	Change From Last Year	10 Year Trend
Gross Profit Margin	0.62	0.4986	Fairly Up	Slightly volatile

Correlation Analysis. For information on how to trade Standard Stock refer to our How to Invest in Standard Biotools guide.Comparing Standard Biotools' estimated and trailing EPS clarifies whether the earnings trajectory is accelerating or decelerating. Comparing forward and trailing EPS signals whether the earnings trajectory is expanding or contracting. Margin trends and working capital shifts add nuance to Standard Biotools' reported EPS. Estimate dispersion for Standard reflects the degree of uncertainty embedded in current analyst models. The consensus EPS view for Standard Biotools usually references EPS before non-recurring items. These estimates can include stock-based compensation expense. The projected EPS for Standard Biotools is -0.01, scheduled for 30th of June 2026. All data reflects publicly available financial reports.. These projections help frame the earnings trajectory for Standard Biotools across periods. The dataset is based on publicly available financial disclosures.